These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 31062421

  • 1. Effects of dietary calcium to available phosphorus ratios on bone metabolism and osteoclast activity of the OPG /RANK/RANKL signalling pathway in piglets.
    Zhao L, Li M, Sun H.
    J Anim Physiol Anim Nutr (Berl); 2019 Jul; 103(4):1224-1232. PubMed ID: 31062421
    [Abstract] [Full Text] [Related]

  • 2. The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues.
    Zupan J, Komadina R, Marc J.
    J Biomed Sci; 2012 Mar 01; 19(1):28. PubMed ID: 22380539
    [Abstract] [Full Text] [Related]

  • 3. Oral Exposure to ZnO Nanoparticles Disrupt the Structure of Bone in Young Rats via the OPG/RANK/RANKL/IGF-1 Pathway.
    Xu X, Tang Y, Lang Y, Liu Y, Cheng W, Xu H, Liu Y.
    Int J Nanomedicine; 2020 Mar 01; 15():9657-9668. PubMed ID: 33299310
    [Abstract] [Full Text] [Related]

  • 4. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W, Zhang X.
    Mol Med Rep; 2015 May 01; 11(5):3212-8. PubMed ID: 25572286
    [Abstract] [Full Text] [Related]

  • 5. The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification.
    Carrillo-López N, Martínez-Arias L, Alonso-Montes C, Martín-Carro B, Martín-Vírgala J, Ruiz-Ortega M, Fernández-Martín JL, Dusso AS, Rodriguez-García M, Naves-Díaz M, Cannata-Andía JB, Panizo S.
    Nephrol Dial Transplant; 2021 Mar 29; 36(4):618-631. PubMed ID: 33367746
    [Abstract] [Full Text] [Related]

  • 6. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.
    Biochem Pharmacol; 2013 Sep 15; 86(6):782-90. PubMed ID: 23928189
    [Abstract] [Full Text] [Related]

  • 7. Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
    Stuss M, Rieske P, Cegłowska A, Stêpień-Kłos W, Liberski PP, Brzeziańska E, Sewerynek E.
    J Clin Endocrinol Metab; 2013 May 15; 98(5):E1007-11. PubMed ID: 23543663
    [Abstract] [Full Text] [Related]

  • 8. Baicalin Ameliorates Dexamethasone-Induced Osteoporosis by Regulation of the RANK/RANKL/OPG Signaling Pathway.
    Zhao Y, Wang HL, Li TT, Yang F, Tzeng CM.
    Drug Des Devel Ther; 2020 May 15; 14():195-206. PubMed ID: 32021104
    [Abstract] [Full Text] [Related]

  • 9. (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.
    Shen Y, Jiang T, Wang R, He S, Guo M, Zuo J, He D.
    BMC Complement Altern Med; 2015 Mar 24; 15():77. PubMed ID: 25887296
    [Abstract] [Full Text] [Related]

  • 10. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG, Kim JH, Kim JY, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM.
    Menopause; 2007 Mar 24; 14(5):913-8. PubMed ID: 17667143
    [Abstract] [Full Text] [Related]

  • 11. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C, Gourgiotis D, Kossiva L, Doulgeraki A, Marmarinos A, Galli-Tsinopoulou A, Karavanaki K.
    Osteoporos Int; 2016 Apr 24; 27(4):1631-1643. PubMed ID: 26588909
    [Abstract] [Full Text] [Related]

  • 12. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.
    J Bone Miner Res; 2005 Sep 24; 20(9):1659-68. PubMed ID: 16059637
    [Abstract] [Full Text] [Related]

  • 13. Zinc supplements and bone health: The role of the RANKL-RANK axis as a therapeutic target.
    Amin N, Clark CCT, Taghizadeh M, Djafarnejad S.
    J Trace Elem Med Biol; 2020 Jan 24; 57():126417. PubMed ID: 31653549
    [Abstract] [Full Text] [Related]

  • 14. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
    Chen T, Feng X.
    Assay Drug Dev Technol; 2006 Aug 24; 4(4):473-82. PubMed ID: 16945019
    [Abstract] [Full Text] [Related]

  • 15. Zebrafish scales respond differently to in vitro dynamic and static acceleration: analysis of interaction between osteoblasts and osteoclasts.
    Kitamura K, Takahira K, Inari M, Satoh Y, Hayakawa K, Tabuchi Y, Ogai K, Nishiuchi T, Kondo T, Mikuni-Takagaki Y, Chen W, Hattori A, Suzuki N.
    Comp Biochem Physiol A Mol Integr Physiol; 2013 Sep 24; 166(1):74-80. PubMed ID: 23632157
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
    Takayama K, Inoue T, Narita S, Maita S, Huang M, Numakura K, Tsuruta H, Saito M, Maeno A, Satoh S, Tsuchiya N, Habuchi T.
    Cancer Lett; 2017 Jul 01; 397():103-110. PubMed ID: 28373003
    [Abstract] [Full Text] [Related]

  • 17. Effect of cadmium on osteoclast differentiation during bone injury in female mice.
    He S, Zhuo L, Cao Y, Liu G, Zhao H, Song R, Liu Z.
    Environ Toxicol; 2020 Apr 01; 35(4):487-494. PubMed ID: 31793751
    [Abstract] [Full Text] [Related]

  • 18. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH, Kirschenbaum A, Yao S, Levine AC.
    Endocrinology; 2005 Apr 01; 146(4):1991-8. PubMed ID: 15618359
    [Abstract] [Full Text] [Related]

  • 19. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis.
    Samara S, Dailiana Z, Chassanidis C, Koromila T, Papatheodorou L, Malizos KN, Kollia P.
    Exp Mol Pathol; 2014 Feb 01; 96(1):9-14. PubMed ID: 24200492
    [Abstract] [Full Text] [Related]

  • 20. IL-3 Differentially Regulates Membrane and Soluble RANKL in Osteoblasts through Metalloproteases and the JAK2/STAT5 Pathway and Improves the RANKL/OPG Ratio in Adult Mice.
    Singh K, Piprode V, Mhaske ST, Barhanpurkar-Naik A, Wani MR.
    J Immunol; 2018 Jan 15; 200(2):595-606. PubMed ID: 29203513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.